30
Participants
Start Date
August 3, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
Selinexor
"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
Rituximab
Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
Methotrexate
high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
RECRUITING
Department of Hematology, Huashan Hospital, Fudan University, Shanghai
NOT_YET_RECRUITING
Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital Of Anhui Medical University, Hefei
NOT_YET_RECRUITING
Beijing Tiantan Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
The First Affiliated Hospital Of Fujian Medical University, Fuzhou
Antengene Corporation
INDUSTRY
Tong Chen, MD
OTHER